Agent | FDA pregnancy category | Adverse effects in human pregnancy | Summary risk assessment |
---|---|---|---|
Etanercept | B | No documented increased risk for structural defects | Based on minimal data in human pregnancy, teratogenic risk is undetermined |
Infliximab | B | Â | Â |
Adalimumab | B | Â | Â |
Rituximab | C | No documented increased risk for structural defects based on case report | Based on lack of data in human pregnancy, teratogenic risk is undetermined |
Anakinra | B | No available human data | Based on lack of data in human pregnancy, teratogenic risk is undetermined |